150 related articles for article (PubMed ID: 27881052)
1. Prognostic value of lactate dehydrogenase in Chinese patients with newly diagnosed transplant eligible multiple myeloma.
Huang B; Lu J; Wang X; Xiao Y; Zhao Y; Huang H; Liu J; Chen M; Gu J; Yuan S; Zheng D; Li Y; Huang X; Li J
Leuk Lymphoma; 2017 Jul; 58(7):1740-1742. PubMed ID: 27881052
[No Abstract] [Full Text] [Related]
2. High serum lactate dehydrogenase predicts an unfavorable outcome in Chinese elderly patients with multiple myeloma.
Gu Y; Yuan YH; Xu J; Shi QL; Qu XY; Guo R; Bai H; Xu JD; Li JY; Chen LJ
Oncotarget; 2017 Jul; 8(29):48350-48361. PubMed ID: 28418851
[TBL] [Abstract][Full Text] [Related]
3. Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents.
Maltezas D; Dimopoulos MA; Katodritou I; Repousis P; Pouli A; Terpos E; Panayiotidis P; Delimpasi S; Michalis E; Anargyrou K; Gavriatopoulou M; Stefanoudaki A; Tzenou T; Koulieris E; Sachanas S; Dimou M; Vassilakopoulos TP; Angelopoulou MK; Pangalis GA; Kyrtsonis MC
Hematol Oncol; 2013 Jun; 31(2):96-102. PubMed ID: 22961993
[TBL] [Abstract][Full Text] [Related]
4. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
[TBL] [Abstract][Full Text] [Related]
5. Revised International Staging System Applied to Real World Multiple Myeloma Patients.
Jimenez-Zepeda VH; Duggan P; Neri P; Rashid-Kolvear F; Tay J; Bahlis NJ
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):511-518. PubMed ID: 27425179
[TBL] [Abstract][Full Text] [Related]
6. Beta-2-microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Stella-Holowiecka B; Czerw T; Holowiecka-Goral A; Giebel S; Wojnar J; Holowiecki J
Transplant Proc; 2007 Nov; 39(9):2893-7. PubMed ID: 18022010
[TBL] [Abstract][Full Text] [Related]
7. Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma.
Shin HJ; Kim K; Lee JW; Song MK; Lee JJ; Lee HS; Lee WS; Kim SJ; Chung JS
Eur J Haematol; 2014 Nov; 93(5):414-21. PubMed ID: 24813053
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation.
Çiftçiler R; Göker H; Demiroğlu H; Haznedaroğlu İC; Sayınalp N; Aksu S; Özcebe O; Büyükaşık Y
Turk J Haematol; 2021 Feb; 38(1):33-40. PubMed ID: 32539315
[TBL] [Abstract][Full Text] [Related]
9. Serum Lactate Dehydrogenase Can Be Used as a Factor for Re-Evaluating First-Relapsed Multiple Myeloma.
Liu Y; Wen L; Chen H; Chen Y; Duan W; Kang Y; Ma L; Huang X; Lu J
Acta Haematol; 2020; 143(6):559-566. PubMed ID: 32610311
[TBL] [Abstract][Full Text] [Related]
10. [Multiple myeloma--new therapeutic perspectives].
Skotnicki AB; Wolska-Smoleń T; Jurczyszyn A
Przegl Lek; 1999; 56 Suppl 1():67-72. PubMed ID: 10494186
[TBL] [Abstract][Full Text] [Related]
11. Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse.
Radocha J; Pour L; Pika T; Maisnar V; Špička I; Gregora E; Krejčí M; Minařík J; Machálková K; Straub J; Pavlíček P; Hájek R; Žák P
Eur J Haematol; 2016 Feb; 96(2):119-27. PubMed ID: 25816709
[TBL] [Abstract][Full Text] [Related]
12. The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC equations?
Terpos E; Christoulas D; Kastritis E; Katodritou E; Pouli A; Michalis E; Papassotiriou I; Dimopoulos MA;
Eur J Haematol; 2013 Oct; 91(4):347-55. PubMed ID: 23829647
[TBL] [Abstract][Full Text] [Related]
13. Using Both Lactic Dehydrogenase Levels and the Ratio of Involved to Uninvolved Free Light Chain Levels as Risk Factors Improves Risk Assessment in Patients With Newly Diagnosed Multiple Myeloma.
Guo Z; Li H; Geng Y; Cui J; Tang N; Li D
Am J Med Sci; 2018 Apr; 355(4):350-356. PubMed ID: 29661348
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.
Kyrtsonis MC; Vassilakopoulos TP; Kafasi N; Sachanas S; Tzenou T; Papadogiannis A; Galanis Z; Kalpadakis C; Dimou M; Kyriakou E; Angelopoulou MK; Dimopoulou MN; Siakantaris MP; Dimitriadou EM; Kokoris SI; Panayiotidis P; Pangalis GA
Br J Haematol; 2007 May; 137(3):240-3. PubMed ID: 17408464
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.
Jurczyszyn A; Nahi H; Avivi I; Gozzetti A; Niesvizky R; Yadlapati S; Jayabalan DS; Robak P; Pika T; Andersen KT; Rasche L; Mądry K; Woszczyk D; Raźny M; Usnarska-Zubkiewicz L; Knopińska-Posłuszny W; Wojciechowska M; Guzicka-Kazimierczak R; Joks M; Grosicki S; Ciepłuch H; Rymko M; Vesole DH; Castillo JJ
Br J Haematol; 2016 Dec; 175(5):884-891. PubMed ID: 27682187
[TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance imaging pattern of bone marrow involvement as a new predictive parameter of disease progression in newly diagnosed patients with multiple myeloma eligible for autologous stem cell transplantation.
Song MK; Chung JS; Lee JJ; Min CK; Ahn JS; Lee SM; Shin DY; Bae SH; Hong J; Lee GW; Lee IS; Shin HJ
Br J Haematol; 2014 Jun; 165(6):777-85. PubMed ID: 24628463
[TBL] [Abstract][Full Text] [Related]
17. Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death.
Moreau P; Cavo M; Sonneveld P; Rosinol L; Attal M; Pezzi A; Goldschmidt H; Lahuerta JJ; Marit G; Palumbo A; van der Holt B; Bladé J; Petrucci MT; Neben K; san Miguel J; Patriarca F; Lokhorst H; Zamagni E; Hulin C; Gutierrez N; Facon T; Caillot D; Benboubker L; Harousseau JL; Leleu X; Avet-Loiseau H; Mary JY
J Clin Oncol; 2014 Jul; 32(20):2173-80. PubMed ID: 24888806
[TBL] [Abstract][Full Text] [Related]
18. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents.
Terpos E; Katodritou E; Roussou M; Pouli A; Michalis E; Delimpasi S; Parcharidou A; Kartasis Z; Zomas A; Symeonidis A; Viniou NA; Anagnostopoulos N; Economopoulos T; Zervas K; Dimopoulos MA;
Eur J Haematol; 2010 Aug; 85(2):114-9. PubMed ID: 20477863
[TBL] [Abstract][Full Text] [Related]
19. Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma.
Mylin AK; Abildgaard N; Johansen JS; Heickendorff L; Kreiner S; Waage A; Turesson I; Gimsing P;
Leuk Lymphoma; 2015; 56(9):2650-9. PubMed ID: 25573204
[TBL] [Abstract][Full Text] [Related]
20. Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment.
Terpos E; Migkou M; Christoulas D; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Kanellias N; Iakovaki M; Panagiotidis I; Ziogas DC; Fotiou D; Kastritis E; Dimopoulos MA
Blood Cancer J; 2016 May; 6(5):e428. PubMed ID: 27232930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
